Q&A: BioMarin commercial chief Jeff Ajer gears up for biggest drug launch to date — with another waiting in the wings

Beth Snyder Bulik

Senior Editor

Is BioMarin’s chief commercial officer ready to get off the company’s rollercoaster ride of the past few years? Not necessarily. As CCO Jeff Ajer says …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: BioMarin commercial chief Jeff Ajer gears up for biggest drug launch to date — with another waiting in the wings

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Q&A: Bio­Marin com­mer­cial chief Jeff Ajer gears up for biggest drug launch to date — with an­oth­er wait­ing in the wings

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Q&A: BioMarin commercial chief Jeff Ajer gears up for biggest drug launch to date — with another waiting in the wings

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra